Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310799 | 0.85 | QDPR (0.48) | QDPRCNR2 | |
| SCHEMBL22725496 | 0.68 | KDM4E (0.56) | EGFRCNR2 | |
| SCHEMBL21311076 | 0.67 | HTR1D (0.41) | CNR2 | |
| SCHEMBL15030369 | 0.65 | QDPR (0.64) | QDPR | |
| SCHEMBL15317629 | 0.64 | QDPR (0.54) | QDPR | |
| SCHEMBL21311103 | 0.64 | CNR2 (0.34) | EGFRCNR2 | |
| SCHEMBL23123775 | 0.63 | QDPR (0.52) | QDPR | |
| SCHEMBL29789851 | 0.63 | QDPR (0.52) | QDPR | |
| SCHEMBL7744453 | 0.63 | QDPR (1.00) | QDPR | |
| SCHEMBL22725488 | 0.62 | CNR2 (0.33) | EGFRCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | QDPR 2292/4885EGFR 1/4885CNR2 1261/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | QDPR 1871/4885EGFR 1/4885CNR2 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.